4.89
-0.15 (-2.98%)
| Previous Close | 5.04 |
| Open | 5.05 |
| Volume | 4,195,832 |
| Avg. Volume (3M) | 4,343,034 |
| Market Cap | 1,700,183,680 |
| Price / Sales | 26.17 |
| Price / Book | 5.48 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Nuvation Bio Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 62.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 25,954,439 |
| Omega Fund Management, Llc | 31 Dec 2025 | 8,081,089 |
| Laurion Capital Management Lp | 31 Dec 2025 | 7,852,638 |
| Tang Capital Management Llc | 31 Dec 2025 | 3,857,457 |
| Abrams Capital Management, L.P. | 31 Dec 2025 | 3,811,513 |
| Redmile Group, Llc | 31 Dec 2025 | 3,163,256 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (RBC Capital, 165.85%) | Buy |
| Median | 11.00 (124.95%) | |
| Low | 7.00 (UBS, 43.15%) | Hold |
| Average | 10.33 (111.25%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 4.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 13.00 (165.85%) | Buy | 4.36 |
| UBS | 03 Mar 2026 | 7.00 (43.15%) | Hold | 4.36 |
| Wedbush | 10 Feb 2026 | 11.00 (124.95%) | Buy | 5.71 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |